Ovarian Cancer Global Market Report 2025

Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive organs responsible for producing eggs (ova) and hormones such as estrogen and progesterone. It can originate in different parts of the ovaries, including the surface epithelium, germ cells, or stroma.

The primary types of ovarian cancer include epithelial ovarian tumors, ovarian germ cell tumors, ovarian stromal tumors, and primary peritoneal carcinoma. Epithelial ovarian tumors arise from the epithelial cells that form the outer lining of the ovaries. Treatment options include chemotherapy, targeted therapy, radiation therapy, immunotherapy, hormonal therapy, and surgery. These treatments are administered through various routes, such as oral, parenteral, and other methods, and are utilized by different end-users, including hospitals, diagnostic centers, drug stores, online pharmacies, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The ovarian cancer market research report is one of a series of new reports from The Business Research Company that provides ovarian cancer market statistics, including the ovarian cancer industry global market size, regional shares, competitors with the ovarian cancer market share, detailed ovarian cancer market segments, market trends, and opportunities, and any further data you may need to thrive in the ovarian cancer industry. This ovarian cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ovarian cancer market size has grown rapidly in recent years. It will grow from $3.67 billion in 2024 to $4.35 billion in 2025 at a compound annual growth rate (CAGR) of 18.6%. The growth in the historic period can be attributed to increasing number of elderly population, rising incidence of ovarian cancer cases, increasing prevalence of ovarian cancer, rise in government initiatives, growing healthcare spending.

The ovarian cancer market size is expected to see rapid growth in the next few years. It will grow to $8.52 billion in 2029 at a compound annual growth rate (CAGR) of 18.3%. The growth in the forecast period can be attributed to increased research on targeted therapies and personalized medicine, growing geriatric population, rising healthcare awareness, rising ovarian cancer prevalence, rising healthcare expenditures. Major trends in the forecast period include innovative therapies, advancements in radiation therapy, advanced healthcare infrastructure, technological advancements, adoption of novel drugs.

The forecast of 18.3% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of Poly (ADP-ribose) polymerase inhibitor(PARP inhibitors) by inflating prices of olaparib and genetic testing kits developed in the UK and Belgium, resulting in delayed precision therapy and higher gynecologic oncology expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing female population is anticipated to drive the expansion of the ovarian cancer market. The female population refers to the total number of females residing in a specific region or worldwide at a given time. This increase is influenced by factors such as higher life expectancy, improved healthcare, and demographic changes. Ovarian cancer treatments, including surgery, chemotherapy, targeted therapy, and immunotherapy, support the female population by removing cancerous cells, slowing disease progression, alleviating symptoms, and improving survival rates. These treatments ultimately enhance quality of life and provide hope for better long-term outcomes. For example, according to the Census Bureau, a US-based government agency, as of July 2022, the United States had an estimated female population of approximately 168 million, including about 1.9 million females aged 85 and older. Furthermore, a report published in December 2022 by CEIC Data, a UK-based financial services company, indicated that the number of females aged 15-64 reached 2,951,856 in 2022, up from 2,940,645 in 2021. As a result, the rising female population is contributing to the growth of the ovarian cancer market.

Companies in the ovarian cancer market are prioritizing advanced solutions, such as AI platforms, to enhance the accuracy of complex medical data analysis. An AI platform for ovarian cancer is a technology-driven system that utilizes artificial intelligence (AI) and machine learning (ML) to improve various aspects of ovarian cancer care. These platforms integrate medical imaging, genomic data, electronic health records (EHRs), and real-time analytics to support early detection, diagnosis, personalized treatment planning, and patient monitoring. For example, in February 2024, AIIMS Delhi, in collaboration with CDAC Pune, an India-based organization, introduced iOncology.ai, an AI-powered platform for the early detection of breast and ovarian cancer. This platform employs deep learning models to analyze radiological and histopathological images with high accuracy, aiming to improve early diagnosis and survival rates. Already implemented in multiple hospitals, iOncology.ai integrates with the healthcare system to provide risk assessments and recommend mammograms, particularly benefiting women in rural areas. This initiative is part of a broader effort to incorporate AI into healthcare and alleviate pressure on medical facilities.

In February 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired ImmunoGen Inc. for an undisclosed amount. The acquisition aimed to enhance AbbVie's oncology portfolio by incorporating ImmunoGen's innovative antibody-drug conjugate, ELAHERE, alongside other promising cancer therapies. ImmunoGen Inc. is a US-based biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of ovarian cancer.

Major players in the ovarian cancer market are Pfizer Incorporated, Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer Aktiengesellschaft, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Novogen Limited, Oasmia Pharmaceutical AB, Clovis Oncology Inc., Aeterna Zentaris Inc., Allarity Therapeutics Inc., Ellipses Pharma Ltd.

North America was the largest region in the ovarian cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ovarian cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ovarian cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ovarian cancer market consists of revenues earned by entities by providing services such as screening and early detection services, diagnostic imaging services, surgical treatment services, clinical trial services, and palliative and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The ovarian cancer market also includes sales of taxane-based chemotherapy, surgical treatment devices, radiation therapy equipment, angiogenesis inhibitors, and checkpoint inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ovarian Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ovarian cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ovarian cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ovarian cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Epithelial Ovarian Tumors; Ovarian Germ Cell Tumors; Ovarian Stromal Tumors; Primary Peritoneal Carcinoma
• 2) By Treatment: Chemotherapy; Targeted Therapy; Radiation Therapy; Immunotherapy; Hormonal Therapy; Surgery
• 3) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
• 4) By End-user: Hospitals; Diagnostic Centers; Drug Stores; Online Pharmacies; Other End Users
• Subsegments:
• 1) By Epithelial Ovarian Tumors: Serous Carcinoma; Mucinous Carcinoma; Endometrioid Carcinoma; Clear Cell Carcinoma; Brenner Tumors
• 2) By Ovarian Germ Cell Tumors: Dysgerminoma; Teratoma; Yolk Sac Tumor; Embryonal Carcinoma; Choriocarcinoma
• 3) By Ovarian Stromal Tumors: Granulosa Cell Tumors; Thecomas; Sertoli-Leydig Cell Tumors
• 4) By Primary Peritoneal Carcinoma: High-Grade Serous Carcinoma; Low-Grade Serous Carcinoma
• Companies Mentioned: Pfizer Incorporated; Johnson & Johnson Services Inc.; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.; Bayer Aktiengesellschaft; Sanofi S.A.; AstraZeneca PLC; Abbott Laboratories; GlaxoSmithKline plc; Eli Lilly and Company; Boehringer Ingelheim GmbH; Bausch Health Companies Inc.; Bristol-Myers Squibb Company; Sun Pharmaceutical Industries Limited; Cipla Limited; Hikma Pharmaceuticals PLC; Lupin Limited; Novogen Limited; Oasmia Pharmaceutical AB; Clovis Oncology Inc.; Aeterna Zentaris Inc.; Allarity Therapeutics Inc.; Ellipses Pharma Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.